[Pharmacoeconomics of vaccinations in chronic obstructive pulmonary disease].
In this study basic types of pharmacoeconomics analysis are presented. Selected publications concerned influenza vaccinations in risk groups have been discussed. In age groups higher then 65 years costs of treatment are connected with rates of complications and hospitalisations. In COPD patients' pharmacoeconomic analysis shows positive results in more advanced age-groups. In Str. pneumoniae vaccination 23-valent vaccines are more clinically effective. COPD patients Streptococcus pneumoniae vaccination give better pharmacoeconomic results in higher age-groups.
Słominski
J Marek
JM
Klinika Pneumonologii Katerdy Pneumonologii i Alergologii Akademii Medycznej w Gdańsku.
Kubiak
Anna
A
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D006801:Humans; D007252:Influenza Vaccines / Q000191:economics*; D007251:Influenza, Human / Q000150:complications / Q000517:prevention & control*; D011008:Pneumococcal Infections / Q000150:complications / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics*; D011044:Poland; D029424:Pulmonary Disease, Chronic Obstructive / Q000191:economics* / Q000382:microbiology / Q000517:prevention & control*
D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines